Cargando…
Investigating the Efficacy and Safety of Thalidomide for Treating Patients With ß-Thalassemia: A Meta-Analysis
At present, the main therapies for ß-thalassemia patients include regular blood transfusion and iron chelation, associating with a number of limitations. Thalidomide, a fetal hemoglobin (HbF) inducer that promotes γ-globin gene expression, has been reported to be effective for ß-thalassemia. Thus, t...
Autores principales: | Lu, Yanfei, Wei, Zhenbin, Yang, Gaohui, Lai, Yongrong, Liu, Rongrong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786914/ https://www.ncbi.nlm.nih.gov/pubmed/35087410 http://dx.doi.org/10.3389/fphar.2021.814302 |
Ejemplares similares
-
Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or Thalassemia
por: Chen, Yaocheng, et al.
Publicado: (2020) -
Magnetic Resonance Imaging Quantification of the Liver Iron Burden and Volume Changes Following Treatment With Thalidomide in Patients With Transfusion-Dependent ß-Thalassemia
por: Che, Jinlian, et al.
Publicado: (2022) -
Efficacy of Thalidomide Treatment in Children With Transfusion Dependent β-Thalassemia: A Retrospective Clinical Study
por: Li, Xinyu, et al.
Publicado: (2021) -
Erythropoiesis and Iron Homeostasis in Non-Transfusion-Dependent Thalassemia Patients with Extramedullary Hematopoiesis
por: Huang, Yumei, et al.
Publicado: (2019) -
Imbalance of erythropoiesis and iron metabolism in patients with thalassemia
por: Huang, Yumei, et al.
Publicado: (2019)